Zero Bio Ventures backs exceptional founders building transformative life science companies at the frontier of biology and medicine.
Read our thesis →Thesis
01
Platform Biology
The most defensible companies in biotech own repeatable biological platforms, not single assets. We invest where the platform, not the drug, creates durable value.
02
Diagnostics & Data
The next generation of medicine is predictive. We back companies using novel diagnostics, biomarkers, and biological data to redefine how disease is detected and monitored.
03
Therapeutic Modalities
From gene editing to targeted protein degradation, we invest at the frontier of modality development where scientific risk and return potential are most compelling.
Investment Focus
Stage
Seed & Series A
Check Size
$500K – $5M
Sectors
Oncology · Gene Therapy · Diagnostics · Rare Disease
Portfolio
Helix Therapeutics
Next-generation RNA therapeutic platform targeting undruggable disease mechanisms.
Novagen Bio
Protein engineering for precision oncology, leveraging novel antibody conjugation chemistry.
QuantaPath Diagnostics
Liquid biopsy platform enabling ultra-early cancer detection from circulating biomarkers.
CellAxis Sciences
Cell therapy manufacturing at scale, reducing cost and time-to-patient by an order of magnitude.
Meridian Genomics
Population-scale genomic data infrastructure powering drug target discovery and validation.
Luminary Bio
Photoreceptor regeneration for inherited retinal diseases through targeted gene therapy.
Team
Managing Partner
James Liu has 18 years at the intersection of biotech investing and entrepreneurship. He previously led life science investments at two top-tier venture funds and served on the boards of companies acquired by major pharmaceutical companies.
Connect
New York, NY